[Report] Dainippon Sumitomo Pharma Co Ltd PharmaVitae Profile Market Research, Trends, Analysis TOC

CHAPTER 1 EXECUTIVE SUMMARY
- Key findings
- Historical and forecast ethical sales performance
- Therapeutic strategy
- Launch and expiry outlook
- Externalization, geographic and molecule type strategies
  - Externalization strategy
  - Geographic strategy
  - Molecule type strategy
- SWOT analysis
  - Strengths
  - Weaknesses
  - Opportunities
  - Threats
CHAPTER 2 CORPORATE HISTORY
- Key findings
- Background
- Key corporate developments
- M&A history
  - Osaka Pharmaceuticals Co. Ltd. acquires Dainippon Pharmaceuticals Company
  - Sumitomo Chemical Company established
  - Divestment of OTC franchises.
  - Merger of Dainippon Pharma Co., Ltd. and Sumitomo Pharmaceuticals Co., Ltd.
- M&A strategy
  - Strengthened portfolio
  - Geographic expansion
- Current corporate structure
  - Pharmaceuticals unit
  - Animal science unit
  - Food science unit
  - Fine chemicals unit
  - Laboratory products unit
- Current management team
CHAPTER 3 HISTORICAL PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate analysis, 2001-06
  - Revenue and growth rate vs. peer set
- Product analysis, 2001-06
  - Growth drivers
    - Amlodin
    - Prorenal
    - Gasmotin
    - Meropen
  - Growth resistors
    - Sumiferon
    - Ebastel
    - Glimicron
    - Growject
- Operating revenue and cost analysis, 2001-06
  - Operating revenue/cost analysis
CHAPTER 4 FORECAST PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate, 2006-12
- Product analysis, 2006-12
  - Growth drivers
    - Irbesartan
    - AmBisome
    - Prorenal
    - Replagal
    - AD-5423
  - Growth resistors
    - Amlodin
    - Ebastel
    - Tagamet
- Therapy area analysis, 2006-12
  - Growth drivers
    - Infectious disease
    - Central nervous system
    - Endocrine, metabolic and genetic disorders
    - Oncology
  - Growth resistors
    - Cardiovascular and hematology
    - Gastroenterology
  - Therapy area focus
- Launches and expiries analysis, 2006-12
  - Launch portfolio
  - Core portfolio
  - Expiry portfolio
  - Launch/core/expiry configuration
- Externalization analysis, 2006-12
- Geographic analysis, 2006-12
- Molecule type analysis, 2006-12
CHAPTER 5 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Cardiovascular & hematology
  - Amlodin
    - Overview
    - Sales forecast
    - Newsflow
    - Competitive landscape
  - Prorenal
    - Overview
    - Sales forecast
    - Newsflow
    - Competitive landscape
  - Irbesartan
    - Overview
    - Sales forecast
    - Newsflow
    - Competitive landscape
- Gastroenterology
  - Gasmotin
    - Overview
    - Sales forecast
    - Newsflow
    - Competitive landscape
- Infectious diseases
  - Meropen
    - Overview
    - Sales forecast
    - Newsflow
    - Competitive landscape
  - AmBisome
    - Overview
    - Sales forecast
    - Newsflow
    - Competitive landscape
  - Sumiferon
    - Overview
    - Sales forecast
    - Newsflow
    - Competitive landscape
- Respiratory
  - Ebastel
    - Overview
    - Sales forecast
    - Newsflow
    - Competitive landscape
- Endocrine, metabolic and genetic disorders
  - Glimicron
    - Overview
    - Sales forecast
    - Newsflow
    - Competitive landscape
    - Competitive landscape
  - Replagal
    - Overview
    - Sales forecast
    - Newsflow
    - Competitive landscape
- R&D pipeline
CHAPTER 6 APPENDIX
- IMS vs. company-reported data reconciliation
- References
- Abbreviations
- Exchange rates
- List of Tables
  - Table 1: Dainippon Sumitomo: Group Corporate Executive Committee
  - Table 2: Peer set overview
  - Table 3: Operating revenue/cost analysis ($m), 2001-06
  - Table 4: Operating cost ratio analysis (% of total revenues), 2001-06
  - Table 5: Product portfolio overview, sales ($m), 2006-12
  - Table 6: Therapy area overview, sales ($m), 2006-12
  - Table 7: Launch portfolio overview, sales ($m), 2006-12
  - Table 8: Core portfolio overview, sales ($m), 2006-12
  - Table 9: Expiry portfolio overview, sales ($m), 2006-12
  - Table 10: Externally developed portfolio ($m), 2006-12
  - Table 11: Molecule type overview, sales ($m), 2006-12
  - Table 12: Key products overview
  - Table 13: Amlodin: overview
  - Table 14: Amlodin: sales forecast ($m), 2006-12
  - Table 15: Amlodin: newsflow
  - Table 16: Prorenal: overview
  - Table 17: Prorenal: sales forecast ($m), 2006-12
  - Table 18: Prorenal: newsflow
  - Table 19: Irbesartan: overview
  - Table 20: Irbesartan: sales forecast ($m), 2006-12
  - Table 21: Irbesartan: newsflow
  - Table 22: Gasmotin: overview
  - Table 23: Gasmotin: sales forecast ($m), 2006-12
  - Table 24: Gasmotin: newsflow
  - Table 25: Meropen: overview
  - Table 26: Meropen: sales forecast ($m), 2006-12
  - Table 27: Meropen: newsflow
  - Table 28: AmBisome: overview
  - Table 29: Ambisome: sales forecast ($m), 2006-12
  - Table 30: Ambisome: newsflow
  - Table 31: Sumiferon: overview
  - Table 32: Sumiferon: sales forecast ($m), 2006-12
  - Table 33: Sumiferon: newsflow
  - Table 34: Ebastel: overview
  - Table 35: Ebastal: sales forecast ($m), 2006-12
  - Table 36: Ebastal: newsflow
  - Table 37: Glimicron: overview
  - Table 38: Glimicron: sales forecast ($m), 2006-12
  - Table 39: Glimicron: newsflow
  - Table 40: Replagal: overview
  - Table 41: Replagal: sales forecast ($m), 2006-12
  - Table 42: Replagal: newsflow
  - Table 43: Dainippon Sumitomo' s R&D pipeline (Phase I-registration)
  - Table 44: Dainippon Sumitomo' s indication broadening pipeline (Phase I-registration)
  - Table 45: Exchange rates, 2006
- List of Figures
  - Figure 1: Historical and forecast ethical sales performance (% CAGR), Dainippon Sumitomo Pharma peer set
  - Figure 2: Therapeutic focus vs. Japanese Pharma peer set (%), 2006
  - Figure 3: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Dainippon Sumitomo
  - Figure 4: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set
  - Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2006
  - Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2012
  - Figure 7: SWOT analysis of Dainippon Sumitomo Pharma
  - Figure 8: M&A/divestment history
  - Figure 9: Current corporate structure
  - Figure 10: Revenue & growth rate (ethical sales) ($m), 2001-06
  - Figure 11: Ethical revenue ($m) and growth rate (%) vs. peer set, 2001-06
  - Figure 12: Growth drivers/resistor products of historical revenue performance ($m), 2001-06
  - Figure 13: Operating revenue/cost analysis ($m), 2001-06
  - Figure 14: Operating cost ratio analysis (% of total revenues), 2001-06
  - Figure 15: Ethical revenue ($m) and growth rate (%), 2006-12
  - Figure 16: Top five products by sales ($m), 2006
  - Figure 17: Top five products by sales ($m), 2012
  - Figure 18: Growth drivers and resistors by product, 2006-12
  - Figure 19: Key strategic products, sales ($m), 2006-12
  - Figure 20: Ethical sales by therapy area ($m), 2006-12
  - Figure 21: Growth drivers and resistors by therapy area ($m), 2006-12
  - Figure 22: Ethical sales by therapy area (%), 2006-12
  - Figure 23: Therapy area focus compared with peer set (% total ethical sales), 2006
  - Figure 24: Therapy area focus compared with peer set (% total ethical sales), 2012
  - Figure 25: Launch schedule, sales ($m), 2006-12
  - Figure 26: Core products sales growth ($m), 2006-12
  - Figure 27: Expiry schedule, sales ($m), 2006-12
  - Figure 28: Launch, core and expiry, sales ($m), 2006-12
  - Figure 29: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Dainippon Sumitomo
  - Figure 30: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set
  - Figure 31: Externalization dependency, sales ($m), 2006-12
  - Figure 32: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2006-12
  - Figure 33: Externalization dependency vs. peer set, % total sales, 2006
  - Figure 34: Externalization dependency vs. peer set, % total sales, 2012
  - Figure 35: Geographical sales breakdown ($m), 2006-12
  - Figure 36: Growth drivers and resistors by geography, sales ($m), 2006-12
  - Figure 37: US dependency vs. peer set, % total sales, 2006
  - Figure 38: US dependency vs. peer set, % total sales, 2012
  - Figure 39: Growth drivers and resistors by molecule type, sales ($m), 2006-12
  - Figure 40: Molecule type sales breakdown ($m), 2006-12
  - Figure 41: Biologics dependency vs. peer set, % total sales, 2006
  - Figure 42: Biologics dependency vs. peer set, % total sales, 2012
  - Figure 43: IMS vs. company-reported ethical sales discrepancy ($m), 2006
  - Figure 44: IMS vs. company-reported ethical sales forecast growth rates (%), 2006-12

Dainippon Sumitomo Pharma Co., Ltd: PharmaVitae Profile

Table of Contents